Key result
Bucindolol increased cAMP levels in human myocardium by a maximum of 1.64-fold over control, exhibiting approximately 60% of the beta-adrenergic agonist activity of xamoterol.
Why the study?
Does bucindolol increase cAMP accumulation in human myocardium?
Does bucindolol increase cAMP accumulation in human myocardium?
Bucindolol exhibits partial beta-adrenergic agonist activity in normal human myocardial tissue, potentially explaining its failure to reduce mortality in heart failure trials.
Answers are grounded in this paper and cite their sources.
May explain bucindolol's neutral HF mortality effect; leaves open confirmation in failing myocardium.
BACKGROUND: Most clinical studies have shown that beta-adrenergic receptor antagonists improve long-term survival in heart failure patients. Bucindolol, a nonselective beta-receptor blocker, however, failed to reduce heart failure mortality in a recent large clinical trial. The reasons for this failure are not known. Bucindolol has partial agonist properties in rat myocardium, but whether it has agonist activity in human heart is controversial. To address this, we measured the ability of bucindolol to increase cAMP accumulation in human myocardium. METHODS AND RESULTS: Myocardial strips ( approximately 1 mm(3)) obtained from rat and nonfailing human hearts were confirmed to be viable for > or = 48 hours in normoxic tissue culture by MTT assay and histology. Freshly isolated strips were exposed to beta-adrenergic antagonists and agonists and assayed for cAMP. In both rat and human strips, the full beta-adrenergic agonist isoproterenol raised cAMP levels by >2.5-fold at 15 minutes. Carvedilol and propranolol had no effect on basal cAMP levels, whereas metoprolol reduced basal cAMP by approximately 25%. In contrast, bucindolol and xamoterol increased cAMP levels in a concentration-dependent manner in both rat and human myocardium (maximum 1.64+/-0.25-fold and 2.00+/-0.27-fold over control, respectively, P<0.01 for human tissue). CONCLUSIONS: Bucindolol exhibits approximately 60% of the beta-adrenergic agonist activity of xamoterol in normal human myocardial tissue.
No takes yet. Share an insight, caveat, or question.
Andréka et al. (2002) studied Normal human myocardial tissue. Bucindolol vs. Control, carvedilol, propranolol, metoprolol, xamoterol was evaluated on cAMP accumulation (1.64-fold increase, p=<0.01). Bucindolol increased cAMP levels in human myocardium by a maximum of 1.64-fold over control, exhibiting approximately 60% of the beta-adrenergic agonist activity of xamoterol.
Synapse has enriched 10 related papers. Consider them for comparative context: